Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection Key PointsQuestionCan observational clinical data from commercial laboratories be used to evaluate the comparative risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for individuals who are antibody positive vs those who are antibody negative? FindingIn this cohort study of more than 3.2 million US patients with a SARS-CoV-2 antibody test, 0.3% of those indexed with positive test results had evidence of a positive nucleic acid amplification test beyond 90 days after index, compared with 3.0% indexed with negative antibody test results. MeaningIndividuals who are seropositive for SARS-CoV-2 based on commercial assays may be at decreased future risk of SARS-CoV-2 infection. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/association-of-sars-cov-2-seropositive-antibody-test-with-risk-of-27UuCU2k4v
Publisher
American Medical Association
Copyright
Copyright 2021 Harvey RA et al. JAMA Internal Medicine.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2021.0366
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionCan observational clinical data from commercial laboratories be used to evaluate the comparative risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for individuals who are antibody positive vs those who are antibody negative? FindingIn this cohort study of more than 3.2 million US patients with a SARS-CoV-2 antibody test, 0.3% of those indexed with positive test results had evidence of a positive nucleic acid amplification test beyond 90 days after index, compared with 3.0% indexed with negative antibody test results. MeaningIndividuals who are seropositive for SARS-CoV-2 based on commercial assays may be at decreased future risk of SARS-CoV-2 infection.

Journal

JAMA Internal MedicineAmerican Medical Association

Published: May 24, 2021

References